(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual revenue growth rate of 85.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.85%.
60 Degrees Pharmaceuticals's revenue in 2025 is $718,262.On average, 1 Wall Street analysts forecast SXTP's revenue for 2025 to be $2,062,047, with the lowest SXTP revenue forecast at $2,062,047, and the highest SXTP revenue forecast at $2,062,047. On average, 1 Wall Street analysts forecast SXTP's revenue for 2026 to be $3,269,818, with the lowest SXTP revenue forecast at $3,269,818, and the highest SXTP revenue forecast at $3,269,818.
In 2027, SXTP is forecast to generate $5,567,528 in revenue, with the lowest revenue forecast at $5,567,528 and the highest revenue forecast at $5,567,528.